Electrocardiographic changes with ziprasidone.
Loebel
Antony
A
Pfizer, Inc., New York.
Miceli
Jeffrey
J
Pfizer, Inc., New York.
Chappell
Phillip
P
Pfizer, Inc., New York.
Siu
Cynthia
C
Data Power (DP), Inc., Ringoes, NJ.
D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003627:Data Interpretation, Statistical; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy*; D012107:Research Design / Q000592:standards / Q000706:statistics & numerical data; D015983:Selection Bias; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D005879:Tourette Syndrome / Q000150:complications
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone